BioSpace News Archive

Licenses Awakn Kare and Certain Healthcare Intellectual Property Assets to New Owners

Sirnaomics Ltd. announced that the Company has established a strategic partnership with EDIRNA Inc., an early-stage biotech company focused on RNA-Editing therapeutic company, for advancing its proprietary “Edit-to-Cure Therapeutics™" platform, targeting diseases with high unmet clinical need.

POXEL SA announces to be the winner of the 2023 edition of the I-nov contest for its program in adrenoleukodystrophy, a rare neurometabolic disease, for which there is currently no treatment.

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 60,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 18,000 shares of Arcutis’ common stock to seven newly hired employees.

Cytokinetics, Incorporated announced that on June 30, 2023 it granted stock options to purchase an aggregate of 77,450 shares of common stock to 5 new employees, whose employment commenced in June 2023, as a material inducement to their employment.

Terns Pharmaceuticals, Inc. announced that it has granted as of July 1, 2023 equity inducement awards to five new employees under the terms of the 2022 Employment Inducement Award Plan.

Merus N.V. (Nasdaq: MRUS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for zenocutuzumab (Zeno) for the treatment of patients with advanced unresectable or metastatic NRG1 fusion (NRG1+) non-small cell lung cancer (NSCLC), following progression with prior systemic therapy.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the appointment of Alyssa Levin as Chief Financial and Business Officer.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 171,400 restricted stock units to 11 newly-hired employees.